Olesoxime

Drug Profile

Olesoxime

Alternative Names: RG-6083; TRO-19622

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trophos
  • Developer Roche; Trophos
  • Class Cholestenones; Neuroprotectants; Oximes; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA A receptor modulators; Mitochondrial permeability transition pore modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinal muscular atrophy
  • Phase II Multiple sclerosis
  • No development reported Huntington's disease
  • Discontinued Amyotrophic lateral sclerosis; Diabetic neuropathies; Neuropathic pain; Non-alcoholic steatohepatitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in European Union (PO)
  • 19 Nov 2015 Phase-II/III clinical trials in Spinal muscular atrophy (In adolescents, In adults, In children) in United Kingdom, Belgium (PO)
  • 19 Nov 2015 Phase-II/III clinical trials in Spinal muscular atrophy (In children, In adolescents, In adults) in Italy (PO) (EudraCT2015-001589-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top